Информация предназначена только для профессионалов в области здравоохранения.
Вы можете зайти как пользователь социальных сетей
Кафедра психиатрии и психосоматики ФППОВ Первого МГМУ им. И.М.Сеченова
Список исп. литературыСкрыть список 1. Alonso G, Phan V, Guillemain I et al. Immunocytochemical localization of the σ-receptor in the adult rat central nervous system. Neuroscience 2000; 97: 155–70. 2. Aydar E, Palmer CP, Klyachko VA, Jackson MB. The sigma receptor as a ligand-regulated auxiliary potassium channel subunit. Neuron 2002; 34: 399–410. 3. Baulieu EE, Robel P, Schumacher M. Neurosteroids: from definition and biochemistry to physiopathologic function. Neurosteroids: a new regulatory function in the nervous system Hamana Press, Totowa, New Jersey, 1999; p. 1–25. 4. Bermackj E, Debonnel G. Modulation of serotonergic neurotransmis sion by short- and long-term treatments with sigma ligands. Br J Phar Macology 2001; 134: 691–6. 5. Chen Y, Hajipour AR, Sievert MK et al. Characterization of the cocaine binding site on the σ1-receptor. Biochemistry 2007; 46: 3532–42. 6. Cobos EJ, Entrena JM, Nieto FR et al. Pharmacology and therapeutic potential of σ1-receptor ligands. Curr Neuropharmacol 2008; 6 (4): 344–66. 7. Dussossoy D, Carayon P, Belugou S et al. Colocalization of sterol isomerase and σ1-receptor at endoplasmic reticulum and nuclear envelope level. Eur J Biochem 1999; 263: 377–86. 8. Earley B, Burke M, Leonard BE et al. Evidence for an anti-amnesic effect of JO 1784 in the rat: a potent and selective ligand for the σ- receptor. Brain Res 1991; 546: 282–6. 9. Furuse T, Hashimoto K. Fluvoxamine monotherapy for psychotic depression: the potential role of σ1-receptors. Ann Gen Psychiatry 2009; 8: 26. 10. Gatti F, Bellini L, Gasperini M et al. Fluvoxamine alone in the treatment of delusional depression. Am J Psychiatry 1996; 153: 414–6. 11. George MS, Guidotti A, Rubinow D et al. CSF neuroactive steroids in affective disorders:pregnenolone, progester one, and DBI. Biol Psychiatry 1994; 35: 775–80. 12. Gombos Z, Spiler A, Cottrell GA et al. Mossy fiber sprouting induced by repeated electroconvulsive shock seizures. Brain Res 1999; 844: 28–33. 13. Hanner M, Moebius FF, Flandorfer A et al. Purification, molecular cloning, and expression of the mammalian σ1-binding site. Proc Natl Acad Sci, USA, 1996; 93: 8072–7. 14. Hashimoto K. σ1-Receptors and selective serotonin reuptake inhibitors: clinical implications of their relationship. Cent Nerv Syst Agents Med Chem 2009; 9: 197–204. 15. Hayashi T, Su TP. Regulating ankyrin dynamics: Roles of σ1-receptors. Proc Natl Acad Sci USA, 2001; 98: 491–6. 16. Hayashi T, Su TP. Understanding the role of σ1-receptors in psychotic depression. Psychiatr Times 2005; 22: 54–63. 17. Hayashi T, Stahl SM: The σ1-receptor and its role in the treatment of mood disorders. Drugs Future 2009, 34: 137–46. 18. Hellewell SB, Bowen WD. A sigma-like binding site in rat phenochro-mocytoma (PC12) cells: Decreased affinity for (+)-benzomorphans and lower molecular weight suggest a different σ-receptor form from that of guinea pig brain. Brain Res 1990; 527: 244–53. 19. Hirschfeld RM. Efficacy of SSRIs and newer antidepressants in severe depression: Comparison with TCAs. J Clin Psychiatry 1999; 60: 326–35. 20. Ishikawa M, Sakata M, Ishii K et al. High occupancy of σ1-receptors in the human brain after single oral administration of donepezil: a positron emission tomography study using [11C]SA4503. Int J Neuropsychopharmacol 2009; 12 (8): 1127–31. 21. Itzhak Y, Stein I, Zhang S-H et al. Binding of a- ligands to C57BL/6 mouse brain membranes: effects of monoamine oxidase inhibitors and subcellular distribution studies suggest the ex istence of a-receptor subtypes. J Pharmacol Exp Therapeutics 1991; 257: 141–8. 22. Kawamura K, Ishiwata K, Tajima H et al. In vivo evaluation of [11C]SA4503 as a PET ligand for mapping CNS sigma, receptors. Nucl Med Biol 2000; 27: 255–61. 23. Klein M, Musacchio JM. Effets of cytochrome P-450 ligands on the binding of [3H]dextrometorphan and sigma ligands to guinea-pig brain. In: Y.Itzhak, ed. Sigma Receptors Academic, San Diego, CA, 1994; p. 243–62. 24. Largent BL, Wikstrom H, Gundlach AL, Snyder SH. Structural determi nants of a receptor affinity. J Pharmacol Exp Therapeutics 1987; 32: 772–84. 25. Langa F, Codony X, Tovar V et al. Generation and phenotypic analysis of sigma receptor type 1 (al) knockout mice. Eur j Neurosci 2003; 18: 2188–96. 26. Leonard BE. The potential contribution of σ-receptors to antide pressant actions. In: Antidepressants: New Pharmacol Strate Gies Ed. P.Skolnick, Humana Press, Totowa, 1997; p. 159–72. 27. Martin WR, Eades JA, Thompson RE et al. The effects of morphine- and nalorphin-like drugs in the nondependent and mor phine-dependent chronic spinal dog. J Pharmacol Exp Ther 1976; 197: 517–32. 28. Matsuno K, Senda T, Kobayashi T et al. SA4503, a novel cognitive enhancer, with σ1-receptor agonistic properties. Behav Brain Res 1997; 83: 221–4. 29. Maurice T, Urani A, Phan V-L, Romieu P. The interaction between neu- roactive steroids and the <rf receptor function: behavioral consequen ces and therapeutic opportunities. Brain Res Rev 2001; 37: 116–32. 30. Maurice T, Su TP. The pharmacology of σ1-receptors. Pharmacol Ther 2009; 124 (2): 195–206. 31. McCann Dj, Su TP. Haloperidol-sensitive (+)-[3H] SKF-10,047 binding sites (a sites) exhibit an unique distribution in rat brain subcellular fractions. Eurj Pharmacol 1990; 188: 211–8. 32. McEwen BS. The neurobiology of stress: from serendipity to clinical relevance. Brain Res 2000; 886: 172–89. 33. Mellon H, Griffin LD. Neurosteroids: biochemistry and clinical signifi cance. Trends in Endcrinol Metab 2002; 13: 35–43. 34. Miyatake R, Furukawa A, Matsushita S et al. Functional polymorphisms in the σ1-receptor gene associated with alcoholism. Biol Psychiatry 2004; 55: 85–90. 35. Monnet FP, de Costa BR, Bowen WD. Differentiation of sigma ligand-activated receptor subtypes that modulate NMDA-evoked adrenaline release in rat hippocampalslices. Br J Pharmacol 1996; 119: 65–72. 36. Monnet FP, Morin-Surun MP, Leger J, Comettes L. Protein kinase C-dependent potentiation of intracellular calcium influx by σ-receptor agonists in rat hippocampal neurons. J Pharmacol Exp Ther 2003; 307: 705–12. 37. Narita N, Hashimoto K, Tomitaka S, Minabe Y. Interactions of selective serotonin reuptake inhibitors with subtypes of a receptors in rat brain. Eur J Pharmac 1996; 307: 117–9. 38. Nestler EJ, Barrot M, DiLeone RJ et al. Neurobiology of depression. Neuron 2002; 34: 13–25. 39. Norrholm S, Ouimet CC. Altered dendritic spine density in animal models of depression and in response to antidepressant treatment. Synapse 2001; 42: 151–63. 40. Nuwayhid S, Werling L. Sigma receptor agonist-mediated regulation of N-methyl-D-aspartate-stimulated [3H]dopamine release is dependent upon protein kinase C. J Pharmacol Exp Ther 2003; 304: 364–9. 41. Pal A, Hajipour AR, Fontanilla D et al. Identification of regions of the σ1-receptor ligand binding site using a novel photoprobe. Mol Pharmacol 2007; 72: 921–33. 42. Palacios G, Muro A, Vela JM et al. Immunohistochemical localization of the σ-receptor in oligodendrocytes in the rat central nervous system. Brain Res 2003; 961: 92–9. 43. Pande A, Geneve J, Scherrer B. Igmesine, a novel sigma ligand, has an tidepressant properties. The 21rd Collegium Internationale Neuro-Psychopharmacologicum 1998; abstract (SM0505) Glasgow. 44. Pande AC, Genève J, Scherrer B et al. A placebo-controlled trial of igmesine in the treatment of major depression. Eur Neuropsychopharmacol 1999; 9: S138. 45. Quirion R, Chicheportiche R, Contrras PC et al. Zukin SR Classification and nomenclature of phencyclidine and σ-receptor sites. Trends Pharmacol Sci 1987; 10: 444–6. 46. Quirion R, Bowen WD, Itzhak Y et al. A proposal for the classification of sigma binding sites. Trends Pharmacol Sci 1992; 13: 85–6. 47. Rao TS, Cler JA, Mick SJ et al. Neurochemical characterization of dopaminergic effects of opipra- mol, a potent σ-receptor ligand, in vivo. Neuropharmacology 1990; 12: 1191–7. 48. Reddy DS, Kaur G, Kulkarni SK. σ1-Receptor mediated antide pressant-like effects of neurosteroids in the Porsolt forced swim test. Neuroreport 1998; 9: 3069–73. 49. Shannon HE. Phencyclidine-like discriminative stimuli of (+)- and (-)- N-allylnormetazocine in rats. Eurj Pharmacol 1982; 84: 225–8. 50. Shirayama Y, Takahashi K, Nishikawa T. Uncompetitive inhibition of [3H]l,3-di-o-tolyl-guanidinepdefined s binding sites by desipramine, propranolol and alprenolol in rat brain. Eur J Pharmacology 1997; 331: 319–23. 51. Skuza G, Rogoz Z. A potential antidepressant activity of SA4503, a selective sigmal receptor agonist. Behav Pharmacol 2002; 13: 537–43. 52. Stahl SM. Antidepressant treatment of psychotic major depression: Potential role of the receptor. CNS Spectr 2005; 10: 319–23. 53. Su TP. Evidence for sigma opioid receptor: binding of [H3] SKF-10047 to etorphine-inaccessible sites in guinea-pig brain. J Pharmacol Exp Ther 1982; 223: 284–90. 54. Su TP, London ED, Jaffe JH. Steroid binding at a receptors suggests a link between endocrine, nervous, and immune systems. Science 1988; 240: 219–21. 55. Su TP, Hayashi T. Understanding the molecular mechanism of σ1-receptors: towards a hypothesis that σ1-receptors are intracellular amplifiers for signal transduction. Curr Med Chem 2003; 10: 2073–80. 56. Takebayashi M, Kagaya A, Uchitomi Y et al. Plasma dehydroepiandrosterone sulfate in major depression. J Neural Transm 1998; 105: 537–42. 57. Takebayashi M, Hayashi T, Su TP. Nerve growth factor-induced neurite sprouting in PC12 cells involves σ1-receptors: Implicastions for antidepressants. J Pharmacol Exp Ther 2002; 303: 1227–37. 58. Tottori K, Miwa T, Uwahodo Y et al. Antide pressant effect of OPC-14523 in the forced swimming test in mice. Jpn J Pharmacol 1997; 73: 59. 59. Tottori K, Miwa T, Uwahodo Y et al. Antidepressant-like responses to the combined sigma and 5-HT1A receptor agonist OPC-14523. Neuropharmacology 2001; 41: 976–88. 60. Urani A, Roman FJ, Phan VL et al. The antidepressant-like effect induced by the σ1-receptor agonists and neuroactive steroids in mice submitted to the forced swimming test. J Pharmacol Exp Ther 2001; 298: 1269–79. 61. Urani A, Romieu P, Portales-Casamar E et al. The anti depressant-like effect induced by the σ1-receptor agonist igme- sine involves modulation of intracellular calcium mobilization. Psychopharmacology 2002; 163: 26–35. 62. van Broekhoven F, Verkes RJ. Neurosteroids in depression: a review. Psychopharmacology 2003; 165: 97–110. 63. Vaupel DB. Naltrexone fails to antagonize the sigma effects of PCP and SKF-10,047 in the dog. Eur J Pharmacol 1983; 92: 269–74. 64. Volz HP, Stoll KD. Clinical trials with sigma ligands. Pharmacopsychiatry 2004; 37: S214–S220. 65. Walker JM, Bowen WD, Walker FO et al. Sigma receptors: Biology and function. Pharmacol Rev 1990; 42: 355–402. 66. Wang M, Seippel L, Purdy RH, Backstrom T. Relationship between symptom severity and steroid variation in women with premenstrual syndrome: study on serum pregnenolone, pregnenolone sulfate, 5a- pregnane-3,20-dione and 3 a-hydroxy-5 a-pregnan-20-one. J Clin En Docrinol Metab 1996; 81: 1076–82. 67. Wolkowitz OM, Reus VI, Roberts E et al. Dehydro epiandrosterone (DHEA) treatment of depression. Biol Psychiatry 1997; 41: 311–8. 68. Wolkowitz OM, Reus VI, Keebler N et al. Double blind treatment of major depression with dehy droepiandrosterone. Am J Psychiatry 1999; 156: 646–9. 69. Zanardi R, Franchini L, Gasperini M et al. Faster onset of action of fluvoxamine in combination with pindolol in the treatment of delusional depression: a controlled study. J Clin Psychopharmacol 1998; 18: 441–6. 70. Zanardi R, Franchini L, Gasperini M et al. Doubleblind controlled trial of sertraline versus paroxetine in the treatment of delusional depression. Am J Psychiatry 1996; 153: 1631–3. 71 Zukin SR, Brady KT, Silfer BL, Balster RL. Behavioral and biochem ical stereoselectivity of sigma opiate. PCP receptors. Brain Res 1984; 294: 74–177.